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Cancer has high morbidity and mortality rates related to medication use and produce a costly impact in 
health care. Thus, patients require constant monitoring and proper coordination of care between different 
professionals. This study aimed to evaluate the impact generated by a Medication Therapy Management 
service (MTM) offered to patients with breast cancer in use of polypharmacy. Observational, exploratory, 
descriptive and retrospective study of a MTM service that included 93 patients. Sociodemographic and 
clinical data related to pharmacotherapy and the processes associated with the systematization of the 
service were collected and analyzed. Patients were followed-up by the MTM service on average for 18 
months (±4.31) and 185 drug-related problems (DRP) were identified, an average of two DRP per patient. 
Of these DRP, 48.11% were resolved and 49.73% were in the resolution process. The most common 
DRP were in the categories of Indication (37.84%), followed by Safety (23.78%). The safety category 
showed the highest resolution rate (59.09%). The study revealed an increased risk of DRP for patients 
with three or more comorbidities and using 5 or more medications. The process of systematization of a 
MTM service in oncology was associated with positive outcomes. 
Keywords: Medication therapy management services. Outcomes Pharmaceutical care. Oncology. Breast 
Cancer.
INTRODUCTION
The so-called non-communicable diseases (NCD) 
are currently the subject of actions and planning by the 
Ministry of Health, through the Health Care Networks 
(HCN). These diseases are associated with increased 
morbidity and mortality leading to negative impact on 
the patient and the healthcare system. Due to its long 
course and the possibility of development of long-
term complications, chronic diseases require constant 
monitoring of clinical parameters, both by professionals 
and by patients themselves, as well as greater coordination 
of care between different professionals and different levels 
of care. Cancer is among these diseases (Brasil, 2011; 
Malta, Merhy, 2010).
Worldwide, breast cancer is what most affects 
women, accounting for about 25% of new cases of 
cancer diagnosed in 2012 (Ferlay et al., 2013). In Brazil, 
according to the National Cancer Institute (INCA), 57,960 
new cases per year will be diagnosed in the biennium 
2016/2017, accounting for 56.20 cases per 100,000 
women. On the other hand, the five-year survival rate has 
increased in most developing countries, with an average of 
85% for this type of cancer (Allemani et al., 2015; Brasil, 
2015a). The improvement in survival is due in part to early 
diagnosis, consolidation of adjuvant treatments as well as 
the improvement of symptoms and the prognosis of the 
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disease, which are essential in most cases (Leal, Cubero, 
Del Giglio, 2010; Liedke, 2006). Hormonal therapy 
becomes important among these adjuvant treatments 
because of its variety of treatment options, good toxicity 
profile and high effectiveness (Leal, Cubero, Del Giglio, 
2010). The anti-estrogens are the basis of this treatment for 
hormone receptor-positive patients, among them stand out 
selective modulators of estrogen receptors, tamoxifen and 
aromatase inhibitors, anastrozole and letrozole (Chabner, 
Longo, 2015).
Along with adjuvant treatments for breast cancer, 
many patients use drugs for associated comorbidities, 
such as hypertension, diabetes mellitus, dyslipidemia 
and obesity (Bonita et al., 2013; Malta et al., 2014). 
These diseases have implications for the survival of 
patients, since the most common cause of deaths is not 
related to breast cancer. It is well known that improved 
glycemic control, cholesterol, blood pressure, among other 
parameters, rely on social, economic, emotional, cultural 
and therapeutic factors, which cannot be understood and 
managed by only one type of professional. Additionally, 
the prevalence of multiple comorbidities leads to a quite 
common event in cancer patients, polypharmacy. This is 
characterized by the use of several drugs for various health 
conditions (in general the use of 5 drugs or more), or to 
treat symptoms generated by the use of other medications 
after adverse reactions, called “prescription cascading”, 
which is common in oncology (Balducci, Goetz-Parten, 
Steinman, 2013). Polypharmacy is often the result of 
prescriptions of medications by different doctors for 
the same patient, often without proper communication 
between them (Ramalho de Oliveira, 2011).
The study of Prithviraj et al. (2012) showed an 
incidence of 80% of polypharmacy among elderly cancer 
patients of an oncology clinic from an US academic 
center, and 41% were associated with inadequate medical 
prescriptions. The use of various prescription drugs or self-
medication favors the appearance of drug-related problems 
(DRP) (Moreira, Boechat, 2009).
DRP are undesirable events experienced by 
the patient that involves, or is suspected to involve, 
medications and that interferes with achieving the 
desired therapeutic goals (Cipolle, Strand, Morley, 2012). 
Johnson and Bootman (1995) in a large outpatient study 
in the United States showed that about 28% of hospital 
admissions were due to morbidity and mortality related 
to drug use. In the context of cancer, Chan et al. (2014) 
showed that 12.4% of hospital admissions of cancer 
patients were due to DRP, half of them preventable.
The provision of medication therapy management 
services (MTM) aims to prevent, identify and resolve 
DRP, reducing morbidity and mortality related to drugs, 
helping patients to achieve positive results with their 
pharmacotherapy and to experience improved clinical 
outcomes (Cipolle, Strand, Morley, 2012; Isetts, 2008; 
Mendonça et al., 2016). MTM is offered when the 
professional applies the theoretical, philosophical and 
methodological framework of Pharmaceutical Care 
Practice in their daily work with patients (Cipolle, Strand, 
Morley, 2012; Ramalho de Oliveira, 2011). This service 
allows the pharmacist to assess the pharmacotherapeutic 
needs of the patient and to make a unique contribution 
towards a more rational use of medications in this 
individual’s everyday life. This is realized using a 
rational, systematic and reproducible decision-making 
process. Thus, the drug therapy is assessed according to 
its appropriateness, effectiveness, safety and convenience 
for each patient (Cipolle, Strand, Morley, 2012). After 
an assessment of all of a patient’s medications and the 
identification of DRP, care plans for each medical condition 
being treated are developed to prevent or resolve DRP, and, 
finally, the patient returns for follow-up evaluations when 
the real outcomes are assessed (Ramalho de Oliveira, 
2011). Recent studies involving cancer patients revealed 
clinical benefits and patients’ satisfaction with MTM 
services. Yeoh, Si and Chew (2013) and Yeoh et al. (2015) 
showed the identification and resolution of a large number 
of DRP in elderly cancer patients, and Lam and Cheung 
(2016) presented an improvement in adherence to oral 
therapy for patients with chronic myelogenous leukemia.
Based on the discussed susceptibility of cancer 
patients to the occurrence of DRP, the deleterious effects 
of these on the health of patients, and the scarcity of 
publications that discuss the impact of MTM services in 
patients with breast cancer, this study aims to elucidate 
the results of a systematization process of a MTM service 
provided to patients in treatment of breast cancer.
MATERIAL AND METHODS 
Study design and participants
This is an observational, exploratory, descriptive 
and retrospective study on a MTM service provided in 
an oncology ambulatory clinic of a tertiary hospital in the 
region of Triângulo Mineiro, Minas Gerais. It is a public 
and university-based hospital considered an important 
reference for patients of medium to high complexity 
utilizing the Sistema Único de Saúde (SUS). It provides 
services to three million people in eighty-six districts of 
Triângulo Mineiro and Alto Paranaíba, in various health 
specialties (Brasil, 2015b).
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Clinical pharmacy services started been provided 
to outpatients in January 2011. Since then, 650 visits 
of patients in adjuvant therapy for breast cancer with 
hormonal therapy have been documented. In May 
2014, it began the process of systematization of the 
practice of clinical pharmacists using the framework of 
pharmaceutical care practice as a theoretical reference 
(Cipolle, Strand, Morley, 2012). This practice was then 
operationalized as the offering of MTM services. As a 
result, clinical pharmacists followed the logical decision-
making process to assess patients’ pharmacotherapeutic 
needs known as Pharmacotherapy Workup (PW). All 
DRP identified by MTM providers were documented and 
categorized into seven categories namely: unnecessary 
drug therapy, need for additional drug therapy, ineffective 
drug, dosage too low, adverse drug reaction, dosage too 
high and noncompliance.
Since then, a pharmacist and four residents have 
offered MTM consultations to 505 patients of the clinic. 
For inclusion in this study, the following criteria were met: 
patients on concomitant use of hormones (anastrozole, 
letrozole or tamoxifen) and medications for associated 
comorbidities, which were cared for by MTM pharmacists 
for more than 10 months, with at least one follow-up 
consultation. The sample consisted of 55 individuals, the 
minimum number according to sample calculation, in 
addition to other 38 obtained by simple random sampling 
to increase the strength of the results, totaling 93 records 
of patients with breast cancer in adjuvant treatment of 
hormonal therapy. The study design, inclusion criteria, 
exclusion and sampling are shown in Figure 1.
Data collection
Data were collected from paper and electronic 
medical records for the period of May 2014 to December 
2015 (20 months).
The instrument for data collection was developed 
and completed by the researchers and was divided into two 
parts. The first, with socio-demographic data of patients 
(age, race/color and marital status, habits and substance use 
like smoking and drinking), and clinical data related to the 
MTM service (number of MTM consultations, medications 
in use and duration of treatment, comorbidities, review of 
systems, referrals to members of the multidisciplinary 
team or other services, and DRP identified, prevented 
and solved with implemented interventions). This data 
allowed the evaluation of the outcomes generated with 
the implementation of the MTM service. The second part 
was made with a checklist (supplementary information) 
related to the patient care process, ensuring that the service 
met the necessary requirements to provide adequate care, 
FIGURE 1 - Sample Selection Flowchart
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as recommended by the Resolution nº 585 of August 29, 
2013 by the Brazilian Federal Council of Pharmacy (CFF, 
2013a).
Organization and analysis of data
Descriptive analysis was performed using frequency 
distribution for categorical variables and measures of 
central tendency (average and median) and dispersion 
(standard deviation) for quantitative variables. These data 
were consolidated and explored in the Microsoft Office 
Excel® 2013 program. For analysis of the factors related 
to the patient (age and comorbidities) and drug therapy 
(number of medications) in the presence and absence 
of DRP, the data were organized in Microsoft Office 
Excel®2013 and analysis was carried out in the software 
Freeware R for the Fisher exact test. The study was 
conducted under a confidence level of 95% and statistical 
significance was set at p ≤ 0.05.
The results of the practice management system is 
presented through a comparative analysis between the 
options contained in the supplementary information, 
constructed in accordance to the articles of the resolution 
nº 585 of August 29, 2013 by the Brazilian Federal Council 
of Pharmacy, and what was offered by the MTM service 
under study. Each topic of the checklist was categorized as 
present or absent, and the results were shown descriptively.
Ethical considerations
This study was approved by the Ethics Committee 
of the Federal University of Uberlândia in accordance 
with the attributions defined in Resolution CNS 466/2012, 
(CEP / UFU - CAAE: 40616414.1.0000.5152) and advice 
under no. 1084730. The use of consent forms was waived 
due to the retrospective design of the study. 
RESULTS AND DISCUSSION
Sample characterization
The median age of the patients was 61 years old (± 
11.92), ranging from 36 to 95 years, predominantly white 
and married, as described in Table I.
The vast majority of patients, 67.74%, was in 
adjuvant treatment for breast cancer with tamoxifen, as 
illustrated in Table I. This is due to the large number of 
patients who started treatment in premenopausal age (36 
to 55 years) and maintained the drug during menopause. 
For tamoxifen, the initial adjuvant treatment time is five 
years, with the possibility of extension to ten years with 
clinical benefits and increase in life expectancy in young 
patients tolerant to the drug (Davies et al., 2013). The 
median duration of treatment with hormone was 49 months 
(± 18.38).
TABLE I - Frequency of sociodemographic characteristics 
of patients assisted by MTM service in an oncology clinic 
of a university hospital from May 2014 to December 2015, 
Uberlândia, MG, 2016
Characteristics N=93 %
Age, years
Median (SD) 61 (±12.23) -
36 - 45 9 9.68
46 - 55 22 23.65
56 - 65 30 32.26
66 - 75 19 20.43
≥ 76 13 13.98
Race
White 55 59.14
Black 6 6.45
Mixed 32 34.41
Marital Status
Single 18 19.35
Married 46 49.46
Divorced 9 9.68
Widow 14 15.06
Cohabiting 1 1.08
Uninformed* 5 5.37
Hormonal Therapy
Anastrozole 22 23.66
Letrozole 8 8.60
Tamoxifen 63 67.74
Smoking Status
Current 7 7.54
Past 17 18.27
Never 61 65.59
Uninformed* 8 8.60
Alcohol Consumption
Alcoholic 1 1.08
Social drinker 18 19.35
Past 3 3.22
Never 60 64.52
Uninformed* 11 11.83
SD = standard deviation. *Uninformed: lack of such a 
characteristic record in databases and searchable documents. 
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The analysis of the use of medications for chronic 
comorbidities or other acute health conditions showed a 
median of 6 (± 3.20) medications per patient, which shows 
the high polypharmacy rate in the sample, considered here 
as the use of more than five drugs for various conditions.
The most prevalent comorbidities in the sample are 
shown in Table II. A median of 2 (± 1.35) comorbidities 
per patient was found, and hypertension was the most 
prevalent condition, affecting 61.3% of patients, followed 
by dyslipidemias, hypothyroidism, diabetes mellitus and 
depression.
The results of this study are similar to those obtained 
by Yeoh et al. (2015) that identified DRP in elderly patients 
undergoing outpatient chemotherapy for cancer in which 
breast cancer was the most prevalent in the sample. 
These researchers also identified a median of 6 drugs 
utilized and 3 comorbidities per patient, and the most 
prevalent conditions were hypertension, dyslipidemia 
and diabetes mellitus. This study calls attention to the 
associated comorbidities of these patients, especially the 
high prevalence of hypothyroidism. This can be attributed 
to the fact that only women were analyzed in the sample, 
mostly elderly, for whom the incidence of hypothyroidism 
is high (Sgarbi et al., 2013).
The symptoms presented by patients relate to the 
most prevalent associated conditions and the effects of 
adjuvant treatment of cancer. General symptoms were 
experienced by most patients, comprising 23.9% of 
the total, followed by symptoms associated with the 
cardiovascular system, 18.2%; nervous system, 11.7%; 
gastrointestinal, 11.5%; and endocrine, 11%.
Drug-related problems
A total of 185 DRP have been identified, which 
corresponds to a median of 2 (± 1.35) DRP per patient, 
similar to that found by Yeoh et al. (2015) that found a 
median of 3 DRP per patient. This result suggests a good 
response in DRP identification by the studied MTM 
service, given that the data approximate to a study of a 
sample size three times larger (294 patients).
The most common categories of DRP identified 
were indication (37.84%), followed by safety (23.78%), 
as described in Table III.
The need for additional drug therapy for prevention 
and/or prophylaxis was the main cause of the DRP in 
the category “Indication”, which can be explained by 
the absence of preventive drug therapy for decreased 
bone mineral density and bone fractures in aromatase 
inhibitors users, especially anastrozole. These adverse 
reactions can reach 15% of patients leading to osteoporosis 
in 11% of cases (Micromedex, 2016). Moreover, other 
needed prophylaxis was absent, such as acetylsalicylic 
acid (ASA), which shows benefits in the prevention of 
cardiovascular events in patients with diabetes mellitus 
(Baigent et al., 2009; Silva et al., 2013).
Patients with osteopenia/osteoporosis confirmed 
by bone densitometry were also missing medications 
TABLE II - Prevalence of comorbid conditions associated with 
breast cancer in patients in adjuvant treatment with hormonal 
therapy assisted by MTM service from May 2014 to December 
2015, Uberlândia, MG, 2016
Comorbidities N (%)
Hypertension 57 (61.3)
Dyslipidemia 30 (32.3)
Hypothyroidism 23 (24.7)
Diabetes Mellitus 19 (20.4)
Depression 16 (17.2)
Osteopenia 6 (6.4)
Osteoporosis 4 (4.3)
Osteoarthritis 3 (3.2)
Alzheimer 2 (2.2)
Others* 9 (9.9)
*Comorbidities found: asthma, epilepsy, chronic myelogenous 
leukemia, heart failure, senile tremor, Parkinson’s disease, gout, 
psoriasis and bipolar disorder.
TABLE III – Drug-related problems identified in patients assisted 
by MTM service from May 2014 to December 2015, Uberlândia, 
MG, 2016
Categories of Drug-Related Problems* N (%)
INDICATION 70 (37.84)
1. Unnecessary drug therapy 15 (21.43)
2. Requires additional drug therapy 55 (78.57)
EFFECTIVENESS 33 (14.84)
3. Requires different drug product 10 (30.30)
4. Dosage too low 23 (69.70)
SAFETY 44 (23.78)
5. Adverse drug reaction 40 (90.90)
6. Dosage too high 4 (9.10)
ADHERENCE 38 (20.54)
7. Non-adherence 38 (100)
Total 185 (100)
*Based on Cipolle, Strand, Morley, 2012.
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that control these conditions, ranging from non-
pharmacological measures to supplementation of calcium 
and vitamin D and bisphosphonate use, according to the 
Osteoporosis Clinical Protocol and Therapeutic Guidelines 
of the Brazilian Ministry of Health (Brasil, 2014). These 
results are similar to those found by Strand et al. (2004), 
which reviewed the clinical and economic outcomes from 
25 years of experience with the practice of pharmaceutical 
care, showing that the need for additional preventive drug 
therapy for osteoporosis, acute myocardial infarction and 
stroke were the most prevalent DRP.
T h e  m a i n  c a u s e  o f  D R P i n  t h e  c a t e g o r y 
“Effectiveness” was ‘dosage too low’ resulting from drug 
and food interactions (69.7%). This DRP was the result 
of a classic interaction between the selective serotonin 
reuptake inhibitors fluoxetine and duloxetine with 
tamoxifen.
Among the DRP in the category “Safety”, adverse 
drug reactions (ADRs) were the most common problems, 
mainly caused by adjuvant treatment with tamoxifen and 
anastrozole, respectively. Tamoxifen was responsible for 
the thickening endometrium and vascular events; while 
anastrozole was associated with bone decalcification. 
Both drugs also led to menopausal symptoms. In relation 
to the DRP in the category “Nonadherence”, forgetting 
medication doses were the most frequent ones.
Of the identified DRP, 48.11% were resolved and 
49.73% were in the process of resolution at the end of 
the study period, as shown in Figure 2. In the analysis by 
the category of DRP, the resolution index were greater 
than 50% for three of the four categories, of which safety 
and adherence stood out with 59.09% and 57.89%, 
respectively. This can be explained by the fact that the 
pharmacists were able to solve a large number of problems 
directly with the patient; without the need to make 
recommendations to other professionals. In the study by 
Yeoh et al. (2015), in 68.2% of cases the main action for 
the resolution of ADRs was patient education. Similarly, in 
Cipolle, Strand and Morley (2012), 80% of interventions 
to address DRP occurred directly between the patient and 
the MTM provider/ pharmacist.
Considering the DRP resolution process, the 
category related to “Indication” had the lowest resolution 
rate (32.86%). One possible explanation for this result 
may be the need to establish institutional agreements that 
support collaborative practice between physicians and 
pharmacists and other healthcare professionals. The drug 
therapy problems in the category “Indication” are types 
of DRP which often requires the involvement of other 
professionals. However, this problem might be minimized 
in the near future due to the resolution nº 586 of August 29, 
2013 by the Federal Council of Pharmacy, which regulates 
pharmacists’ prescribing. This resolution addresses the 
situations in which pharmacists could prescribe under 
collaborative practice agreement with physicians such as 
in following protocols or guidelines for the prevention and 
treatment of osteoporosis (CFF, 2013b).
Unresolved DRP (2.16%) were due to two deaths 
in the last five months of the study. Data of these patients 
were considered as they received MTM services for 15 
months and added relevant information to the study.
The study has listed a total of 174 interventions to 
resolve the identified DRP. The most frequent resolutions 
were: patient education (27.01%), followed by initiation of 
new drug therapy (23.56%), discontinuing (18.39%) and/
or modification of pharmacotherapy (17.82%) followed by 
monitoring of laboratory, clinical and image parameters 
(13.22%).
FIGURE 2 - Total and category of DRP resolution index of DRP identified in patients served by the MTM service. Uberlândia, MG, 
2016. DRP: Drug-related problems. Classification of categories based on Cipolle, Strand, Morley, 2012.
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Figure 3 shows a variation in the identification and 
resolution of DRP per consultation during MTM follow-
up visits, highlighting the importance of continuous 
monitoring of the patient by the pharmacist. A total of 369 
consultations were carried out, with a median of 5 visits 
(±2.42) per patient.
By observing the trend throughout the encounters, it 
is clear that a large number of DRP were identified at the 
first encounters, a period when the MTM pharmacist and 
the patient are building their relationship and trust. It is 
believed that a strong therapeutic relationship favors the 
identification of DRP and, more importantly, the resolution 
of these problems (Cipolle, Strand, Morley, 2012).
As we observed the timing for the resolution of 
DRP, the trend indicates that a certain time is required 
for the service to reach its goals, given that the greatest 
amount of DRP was resolved between the third and fifth 
consultation. This suggests that a certain period of time is 
necessary for the pharmacist to make a proper assessment 
of the patient as a whole and define the therapeutic goals 
for that specific patient with subsequent well-informed 
and successful interventions (Cipolle, Strand, Morley, 
2012). This may be associated with the clinical training 
and expertise of professionals, which was being developed 
during the systematization of the clinical practice through 
a clinical training program.
 A period of stability was evidenced between the 
identification and resolution of DRP after the seventh 
consultation, when these were equivalent, indicating the 
time required for the delivery of an effective service, or a 
service in which MTM providers identify and effectively 
resolve DRP. With a median of five visits, the MTM 
service in this study had an insufficient number of follow-
up visits to reach the equivalency between identifying and 
resolving DRP, which was evidenced by the large number 
of DRP in the process of resolution.
In this sense, managing the practice is essential 
to have a consistent and effective service. The practice 
management system includes the monitoring of the entire 
service, the processes involved and the physical, human 
and financial resources necessary for such (Freitas, 
Ramalho de Oliveira, Perini, 2006). However, it requires 
the employment of a cycle of improvements that suggests 
processes of optimization to be performed continuously 
aiming to improve the quality of the service offered and 
its results (Brasil, 2006).
The association between the presence of DRP and 
age, comorbidities and the number of medications used by 
the patients is shown in Table IV.
Univariate analysis showed that patients with more 
than three comorbidities (p = 0.0141) or using five or 
more drugs (p = 0.0008) were significantly associated 
with a higher risk of developing DRP. This corroborates 
with the findings by Yeoh et al. (2015), who also 
showed statistical significance and an increased risk of 
developing DRP up to nine times for patients who have a 
greater number of comorbidities and medications in use. 
In this analysis, age was not significantly associated with 
the presence of DRP.
These results demonstrate the complexity associated 
with the treatment of breast cancer as showed by the high 
number of medications, comorbidities and DRP identified. 
They also suggest the importance of MTM services for 
these patients as well as the critical role that a robust 
practice management system can have to deliver a high-
quality service (Cipolle, Strand, Morley, 2012).
FIGURE 3 - Identification and resolution of DRP according to the frequency of MTM consultations. Uberlândia, MG, 2016. DRP: 
Drug-related problems.
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Practice management
Minimum standards for a MTM service
The delivery of a MTM service has to follow a path 
that allows for an effective and ethical patient care process 
and an efficient practice management system. This path has 
to agree with the theory that supports the service (Caring 
paradigm, patient-centeredness, and Pharmacotherapy 
work up) and to facilitate the dialogue between the 
theory and the practice in the real world. All these must 
lead to improved clinical outcomes and enhanced patient 
experience (Cipolle, Strand, Morley, 2012; APhA, 2008). 
Figure 4 shows how each step of this path can be essential 
for the success of the MTM service.
The studied MTM service is delivered in an adequate 
physical space that ensures the privacy of the patient 
(furniture, telephone line and computer connected to the 
internet). The space is used exclusively for the service 
during days and times scheduled specifically for the 
delivery of the MTM service. 
The recrui tment  of  pat ients  for  the  MTM 
service usually occurs through referral by other health 
professionals, physicians or multidisciplinary team, 
as set out in Figure 4. In the present study, however, 
it was observed the predominance of active search by 
the pharmacist and sometimes spontaneous demand. 
This form of insertion of patients in the service may, 
however, hinder access and imposes difficulties in the 
consolidation of the service as well as lead to a deficit 
in the number of consultations, impairing the expected 
results.
Sorensen et al. (2016) conducted a study on the 
factors that led to the success of MTM in health systems 
of Minnesota, USA. The results revealed that an open and 
welcoming culture for innovation that privilege patient 
care within the organization, as well as understanding that 
the pharmacist is an available resource that can be involved 
in delivering care to improve clinical outcomes are crucial 
for the establishment and sustainability of an MTM 
service. In the present study, despite the availability of an 
adequate physical structure, understanding the importance 
of the pharmacist in the context of care and a welcoming 
environment for this professional in the oncology sector 
are still a major obstacle. This may have impacted and 
contributed to the difficulty in recruiting patients to the 
service, requiring enrollment by direct means, such as 
active search and spontaneous demand.
Patient care process
T h e  a p p l i c a t i o n  o f  t h e  p r o p a e d e u t i c 
Pharmacotherapy Workup (PW) was done effectively 
by professionals of the MTM service during the study 
period, since this systematic process was not a limiting 
factor for the resolution of DRP. However, a complicating 
factor was the documentation of the data collected as 
the electronic record of the Hospital, the University 
Hospitals Management Application (AGHU), did not 
have the appropriate fields for the documentation of the 
pharmaceutical care processes. As a result, an appropriate 
documentation system was implemented by mid-year 
2014.
For the implementation of the MTM service and for 
sustaining the employed changes, it is necessary a model 
that supports the care provided, including documentation 
standards that facilitate data collection and analysis and a 
collaborative practice. This is critical for patients to reach 
therapeutic success (Sorensen et al., 2016). In the oncology 
outpatient clinic studied, the pharmacists managed to 
overcome this obstacle through the development of a new 
pharmacist documentation template in partnership with the 
Centro de Estudos em Atenção Farmacêutica (Center for 
Pharmaceutical Care Studies) at the Federal University of 
Minas Gerais (CEAF/UFMG). This tool made possible the 
systematic record of the practice as well as the insertion 
of the necessary fields into the general patient record, 
contributing to the dissemination of the information 
generated by the MTM service to other members of the 
healthcare team.
Consultation flow at MTM and collaborative practice
As mentioned above, the vast majority of DRP were 
resolved between the pharmacist and the patient (61.86%). 
TABLE IV - Univariate analysis of the association between 
patient-related factors and the presence of drug-related problems 
(DRP). Uberlândia, MG, 2016
Patient-related factors
DRP 
present 
(n=69)
DRP 
absent  
(n=24)
p value
Age
≤ 60 years 31 12 0.8127
> 60 years 38 12
Associated comorbidities
< 3 comorbidities 37 20 0.0141*
≥ 3 comorbidities 32 4
Medications in use
≤ 5 medications 30 20 0.0008*
> 5 medications 39 4
Fisher’s exact test was used for the univariate analysis. Values 
of p ≤ 0.05 were considered statistically significant. 
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The absence of a collaborative and interdisciplinary 
practice agreement between different professions, as 
shown in Figure 4, impacted the results, given the large 
number of DRP still in process of resolution by the 
end of this study. Interdisciplinary work presupposes 
collaborative work and the establishment of common goals 
between those caring for the same patient. Thus, one of the 
biggest challenges of this practice is intrinsically linked 
to a Cartesian way of preparing health care professionals, 
which prevents this experience (Sousa, Bastos, 2016).
Despite all the challenges encountered in the 
provision of the MTM service, pharmacists made 68 
referrals to other professionals for the resolution of DRP 
or to meet patients’ needs of a different nature. The main 
referrals were made to the following professionals: general 
practitioner (39.71%), medical specialist (23.53%), 
nutritionist (20.59%) and psychologist (7.35%), as well 
as dentists, nurses, social workers and the clinic that was 
the geographic reference for a specific patient.
The average time of follow-up in the MTM service 
during the study period was 18 months (± 4.31). Despite 
the good contact time with the service, the number of 
five visits per patient, or one follow-up visit every three 
months, it can still be considered low considering the 
complexity of the patients. This could be another factor 
that prevented a higher rate of resolution of DRP.
It should be emphasized that the follow-up visits 
and the monitoring of the care plans implemented/ 
interventions are crucial for the consolidation of the 
service. The patient has to experience the continuity of 
care and be certain that all DRP will be monitored and 
resolved in a timely manner and that their treatment will be 
effectively optimized. Cipolle, Strand and Morley (2012) 
stress that pharmaceutical care will only be a patient 
care practice when there is appropriate assessment of the 
patient’s needs, development and implementation of care 
plans and follow-up evaluations to guarantee optimal 
outcomes. This is what differentiates pharmaceutical care 
FIGURE 4 - Flow Diagram of the MTM service* at an oncology clinic. *Adapted diagram of a MTM service described by APhA, 
NACDS (2008). The diagram shows the optimal functioning of the MTM service within an oncology clinic, with all steps of 
pharmaceutical care practice. The symbols + and - represent the appropriate scheduling flow, which should be higher for the members 
of the health team and lower for spontaneous demand and active search. MTM: Medication Therapy Management.
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practice from other interventions such as health education. 
This full process indicates the professional is taking 
responsibility for the results of what he or she does.
CONCLUSIONS
It was clear the positive impact of the MTM service 
within 20 months of study, when the service has been in 
the process of systematization. Patient care was being 
delivered in a suitable environment and using effective 
techniques/processes that led to the resolution of a high 
number of DRP. Regarding the limitations, the results 
show the need for a scheduling system that are shared 
between all members of the team, with awareness of a 
multidisciplinary and interdisciplinary practice of care, 
establishing collaborative actions for the benefit of the 
patient, which could lead to better results.
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SUPPLEMENTARY INFORMATION
Practice Management (Check list)
- Based on Resolution nº 585 of August 29, 2013 the Brazilian 
Federal Council of Pharmacy, mark with “X” the characteristics 
presented by the MTM service.
(   ) Caring relationship centered on the patient. 
(   ) Collaborate with other members of the health team, actions 
for the promotion, protection and recovery of health and the 
prevention of diseases and other health problems.
(   ) Participate in care planning for the patient to safely use 
the necessary medications, in doses, frequency, times, routes 
of administration and adequate duration, contributing to the 
patient’s ability to use the drug therapy and to achieve the 
therapeutic goals.
(   ) Perform pharmacist interventions and develop reports to 
communicate with other members of the health team, with the 
purpose of assisting in the selection, addition, replacement, 
adjustment or interruption of the patient’s pharmacotherapy.
(   ) Participate and promote clinical case discussions in an 
integrated way with the other members of the health team.
(   ) Deliver pharmacy consultation in a consultation office that 
guarantees patient’s privacy.
(   ) Receive patients referred by medical staff.
(   ) Receive patients referred by the multiprofessional team.
(   ) Receive patients referred by spontaneous demand and active 
search.
(   ) Performs pharmacist anamnesis as well as verifies signs and 
symptoms, in order to provide care to the patient. 
(   ) Assess and understand the information in the patient’s chart.
(   ) Organize, interpret and, when necessary, summarize the 
patient’s data in order to perform the pharmacist’s assessment.
(   ) Request laboratory tests, within the scope of its professional 
competence, in order to monitor the results of pharmacotherapy.
(   ) Evaluate the results of clinical and laboratory tests of 
the patient, as an instrument for the individualization of 
pharmacotherapy.
(   ) Monitor therapeutic drug levels by means of clinical 
pharmacokinetic data.
(   ) Determine the patient’s biochemical and physiological 
parameters, for the purposes of monitoring pharmacotherapy 
and health screening.
(   ) Prevent, identify, evaluate and intervenes in drug-related 
events and other problems related to pharmacotherapy.
(   ) Identify, evaluate and intervene in the undesirable and 
clinically significant drug interactions. 
(   ) Elaborate the pharmacist’s care plan for the patient.
(   ) Agree with the patient and, when necessary, with other health 
professionals, the actions of the care plan.
(   ) Perform and register the pharmacist’s interventions with the 
patient, family, caregivers and society.
(   ) Periodically evaluate the results of the implemented 
pharmacist’s interventions, constructing quality indicators of 
the clinical services provided.
(   ) Follow up with the patient and document in the patient’s 
chart.
(   ) Prepare an updated and reconciled list of medications in 
use by the patient during the admission, transfer and discharge 
processes between services and health care levels.
(   ) Prescribe, according to specific legislation, within the scope 
of its professional competence.
(   ) Evaluate and monitor patients’ adherence to treatment, and 
carry out actions for their promotion.
(   ) Inform, guide and educate patients, families, caregivers and 
society about health issues, the rational use of medicines and 
other health technologies.
(   ) Develop educational materials for the promotion, protection 
and recovery of health and prevention of diseases and other 
related problems.
(   ) Act in the process of training and professional development 
of pharmacists.
(   ) Develop and participate in training programs and continuing 
education of human resources in the health area.
(   ) Participate in the coordination, supervision, auditing, 
accreditation and certification of actions and services within the 
scope of the pharmacist’s clinical activities.
(   ) Perform the management of processes and projects, through 
tools and quality indicators of clinical services rendered.
(   ) Search, select, organize, interpret and disseminate 
information that guides the decision making based on evidence, 
in the process of patient care.
(   ) Interpret and integrate data obtained from different sources of 
information in the process of evaluation of health technologies.
(   ) Document the entire work process.
Other observations: _________________________________
__________________________________________________
__________________________________________________
__________________________________________________
__________________________________________________
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